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toma (NB) but long term event free survival remains unsatisfac-
tory. Novel approaches to consolidation and minimal residual
disease therapy are urgently needed. AutoSCT combined with
reduced intensity allogeneic stem cell transplantation (RIAlloSCT)
has the potential to confer a durable graft versus tumor immunity,
but is thought to be limited by signiﬁcant toxicity. We have
investigated the feasibility of consolidation with sequential Auto-
SCT/RIAlloSCT in newly diagnosed patients with HR NB.
Methods: Induction chemotherapy was based on a modiﬁed N7
regimen, with patients obtaining at least a PR eligible for consol-
idation. AutoSCT regimen was: Topotecan 1.5 mg/m2x5d, Car-
boplatin 500 mg/m2x3d, and Thiotepa 300 mg/m2x3d. Siblings
and unrelated cord blood (UCB) units were considered as donor
sources. RIAlloSCT conditioning was: Fludarabine 30 mg/m2x5d,
Busulfan IV 3.2 mg/kgx2d, and Rabbit Anti-thymocyte globulin 2
mg/kgx4d (UCB recipients only). GVHD prophylaxis was Tacroli-
mus and Mycophenolate mofetil. Post-AlloSCT patients received
local RT and cis-retinoic acid. Results: 9 patients have enrolled, of
which 5 received both transplants (1 withdrew prior to RIAlloSCT;
1 progressed after AutoSCT; 2 did not achieve a PR with Induc-
tion). Median time to RIAlloSCT after AutoSCT was 79d (67-
93d). Donor characteristics: UCB 4/6, 5/6, 6/6; related donor 5/6,
6/6 HLA matched. Maximal peripheral chimerism was 99-100%. 4
of 5 patients had some evidence of GVHD. Maximal grade for
acute GVHD: skin and gut, grade 3 (n2), skin only, grade 1
(n1). One patient had chronic liver GVHD. All 5 patients are
alive, with no evidence of disease, with median time from diagnosis
of 41m (26m-50m) [Table 1]. Conclusion: AutoSCT followed by
RIAlloSCT appears feasibile in patients with HR NB. Additional
study of this approach in this group of patients is warranted.
RIAlloSCT Recipients
Age at Dx Stage MYCN Resp PreAllo Mo from Dx
22 mo 4 Amp CR 50
13 mo 4 Amp CR 43
62 mo 4 NonAmp PR 41
21 mo 4 Amp VGPR 40
28 mo 3 Amp PR 26
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SUPERIOR ANTITUMOR IN VITRO RESPONSES OF ALLOGENEIC
MATCHED SIBLING COMPARED TO AUTOLOGOUS PATIENT CD8 T
CELLS
Kausche, S.1, Wehler, T.C.1, Schnuerer, E.1, Lennerz, V.1,
Groene, M.1, Nonn, M.1, Meyer, R.G.1, Huber, C.1, Herr, W.1 1Uni-
versity of Mainz - Department of Medicine III, Mainz, Germany.
Allogeneic cell therapy as a means to break immunotolerance to
solid tumors is increasingly used for cancer treatment. To inves-
tigate cellular alloimmune responses in a human tumor model,
primary cultures were established from renal-cell carcinoma
(RCC) tissues of 56 patients. In 3 patients with stable RCC line and
HLA-identical sibling donor available, allogeneic and autologous
RCC reactivities were compared using mixed lymphocyte/tumor-
cell cultures (MLTCs). In addition to peripheral blood lympho-
cytes, tumor-inﬁltrating lymphocytes were included in the analy-
ses. Responding MLTC lymphocytes were exclusively CD8 T
cells, whereas CD4 T cells or NK cells were never observed.
Sibling MLTC populations showed higher proliferative and cyto-
lytic antitumor responses compared to their autologous counter-
parts. The proportion of CD4CD25FOXP3 regulatory T cells
did not signiﬁcantly differ between autologous and allogeneic lym-
phocyte samples, providing no sufﬁcient explanation for the ob-
served hyperresponsiveness of sibling CD8 T cells. The sibling
MLTC responders originated from the CD8CD62L(high) pe-
ripheral-blood subpopulation containing naive precursor and cen-
tral memory T cells. Limiting dilution cloning failed to establish
cytotoxic T-lymphocyte (CTL) clones from autologous MLTCs
or tumor-inﬁltrating lymphocytes. In contrast, a broad panel of
RCC-reactive CTL clones were expanded from each allogeneic
MLTC. These sibling CTL clones recognized either exclusively
the original RCC tumor line or cross-reacted with non-malignant
kidney cells of patient origin. A minority of CTL clones also
recognized patient-derived hematopoietic cells or other allogeneic
tumor targets. The MHC-restricting alleles for RCC-reactive sib-
ling CTL clones included HLA-A2, -A3, -A11, -A24, and -B7. In
one sibling donor-RCC pair, strongly proliferative
CD3CD16CD57 CTL clones with non-HLA restricted anti-
tumor reactivity were established. Taken together, our results
demonstrate superior tumor-reactive CD8 responses of matched
allogeneic compared to autologous T cells. These data encourage
the generation of antitumor T-cell products from HLA-identical
siblings and their potential use in adoptive immunotherapy of
metastatic RCC patients.
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IN-VITRO ASSESSMENT OF THE EFFECTIVENESS OF BUSULFAN (BU) TO
INDUCE APOPTOSIS AND NECROSIS IN NEUROBLASTOMA (NBL) CELL
LINES AND PRIMARY TUMORS
Olszewski, M.1, Jackson, C.1, Huang, W.1, Tallman, S.1, Kletzel, M.1,2
1Children’s Memorial Hospital Stem Cell Processing and Graft Engi-
neering Laboratory, Chicago, IL; 2Northwestern University Feinberg
School of Medicine, Chicago, IL.
Busulfan is an alkylating agent used routinely before hematopoi-
etic progenitor stem cell transplants. Because the effects of Bu on
NBL cells in the literature is controversial, this study sought to
evaluate the use of Bu to induce apoptosis and necrosis in NBL cell
lines and primary tumors.
NBL cell lines (SKN/DOX-R, SKN/SH, IMR-5 and NGP) and
two NBL primary tumors (M-line and S-line) were harvested and
transferred to 24-well culture plates at a density of 106 cells/ml.
Cells were incubated without Bu (control) and with concentrations
of 0.001, 0.01, and 0.1 mg/ml of Bu. Two methods were used. Flow
cytometry was used to assess cells for apoptosis and necrosis, using
Annexin V and Propidium Iodide (PI), respectively, after 6, 24, 48,
and 72 hours (only 24 hour result shown). Cell viability was also
measured using a MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide) drug sensitivity assay.
Results indicated increased apoptosis and necrosis in cell lines
SKN/SH, SKN/DOX-R, and S-line when compared to the con-
trols at 24 hours (See table). MTT assay demonstrated signiﬁcant
decreased viability with the same cell lines (p-values0.05; 0.037,
0.028, and 0.045, respectively), and no signiﬁcant correlation with
the others.
The ﬁndings suggest that Bu is an effective drug against NBL cell
lines SKN/DOX-R, SKN/SH, and primary tumor S-line at 24
hours. Increasing concentrations show increasing cell death in
these sensitive cell lines. Other cell lines IMR-5, NGP, and pri-
mary tumor M-line did not demonstrate increased cell death with
increased Bu concentrations at 24 hours. Further analysis will
determine if other concentrations and time points show greater
sensitivity of NBL cells to Bu.
Mean Percent Cell Viability compared to Busulfan Concentration at
24 Hours
SKN/SH SKN/DOX-R S-line IMR-5 NGP M-line
0 mg/ml 68 81 50 58 92 56
0.001 mg/ml 26 41 31 64 72 48
0.01 mg/ml 21 27 25 50 88 56
0.1 mg/ml 18 28 21 59 80 59
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STIMULATION OF ANTI-TUMOR IMMUNITY USING DENDRITIC CELL/
TUMOR FUSIONS AND ANTI CD3/CD28
Rosenblatt, J.1, Wu, Z.2, Lenahan, C.1, Vasir, B.2, Bisonette, A.2,
Kufe, D.2, Avigan, D.1 1Beth Israel Deaconess Medical Center, Boston,
MA; 2Dana Farber Cancer Institute, Boston, MA.
We have demonstrated that fusions of patient derived renal cell
carcinoma (RCC) and autologous dendritic cells (DCs) stimulate
anti-tumor immune responses and disease response in a subset of
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patients. However, vaccine efﬁcacy is limited by effector cell dysfunc-
tion and increased presence of regulatory T cells characteristic of
cancer patients. Ligation of CD3/CD28 delivers an antigen-indepen-
dent stimulus to resting T cell populations. We postulated that stim-
ulation with DC/tumor fusions followed by anti-CD3/CD28 would
result in the signiﬁcant expansion of activated T cells targeting tumor
antigens. DCs were generated from adherent mononuclear cells cul-
tured with rhIL-4, GM-CSF and TNF and fused with RCC by
coculture in 50% solution of polyethylene glycol. T cells were stim-
ulated by DC/tumor fusions prior to or following exposure to an-
tiCD3/CD28 antibody coated plates for 48 hours. A dramatic, statis-
tically signiﬁcant, increase in T cell proliferation was observed
following the sequential exposure to DC/RCC fusions and anti-CD3/
CD28 (SI 13.2). In contrast, stimulation by anti-CD3/CD28, DC/
tumor fusions, or anti-CD3/CD28 followed by fusion cells did not
result in signiﬁcant T cell proliferation. Similarly, sequential stimula-
tion byDC/RCC fusion cells followed by anti-CD3/CD28 resulted in
a nearly 8 fold expansion of CD4/CD25 cells (n10, p0.001
compared to unstimulated T cells). A 16 fold increase in CD4/CD25/
CD69 cells was observed consistent with the expansion of activated
T cells. In contrast, exposure to anti-CD3/CD28 alone or anti-CD3/
CD28 followed by stimulation with fusion cells resulted in a 3 fold
expansion of CD4/CD25 T cells and a modest expansion of CD4/
CD25/CD69 cells. In concert with these ﬁndings, IFN production
by CD4 T cells was most pronounced following stimulation with
DC/tumor fusions and expansion with anti-CD3/CD28 (p.01). In 9
experiments, stimulation with DC/RCC fusions followed by expan-
sion with anti-CD3/CD28 also resulted in a 5-fold and 4.6 fold
expansion of CD4/CD25/Foxp3 and IL-10 expressing T cells, re-
spectively. In conclusion, we have demonstrated that stimulation of T
cells by DC/RCC fusions followed by exposure to anti-CD3/CD28
antibodies results in the expansion of tumor reactive T cells that
predominantly express markers of activation. We are developing a
clinical trial in which patients will receive fusion/CD3/CD28 ex-
panded T cells following in vivo depletion of regulatory T cells.
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 T CELLS AS IMMUNOTHERAPY FOR GLIOBLASTOMA MULTIFORME
Suarez, C.1, Bryant, N.L.1, Gillespie, Y.1, Lopez, R.D.1,
Markert, J.M.1, Lamb, L.S.1 1University of Alabama at Birmingham,
Birmingham, AL.
Background:Despite advances in therapy, the survival for glioblas-
toma multiforme (GBM) has remained unchanged for 50 years. We
have investigated a cellular therapeutic therapy based on innate im-
mune recognition of GBM using ex vivo expanded  T cells that are
highly cytotoxic to GBM lines. Unlike 	CD8 cytotoxic T lym-
phocytes,  T cells act directly against stress-associated antigens
expressed on GBM and do not require MHC antigen recognition.
Methods: We examined the circulating  T cell number and
function in healthy controls and patients at speciﬁc times; diagnosis,
1-14 days post resection, and 8-14 weeks post resection. Absolute
lymphocyte and subset counts including  T cell counts were exam-
ined using ﬂow cytometry. Functional response of  T cells was
determined by proliferation in our clinically compliant expansion
procedure and subsequent in vitro and in vivo cytotoxicity assays.
Expansion cultures were harvested after two weeks and enriched for
 T cells by immunomagnetic depletion of CD4 and CD8 T
cells. Cytotoxicity of expanded T cells was evaluated in vitro against
GBM primary tumor cultures, established GBM cell lines and cul-
tured astrocytes. In vivo assays were conducted in athymic nude mice
against new and established luciferase-transduced human U251 GBM
xenografts.
Results: At diagnosis, the circulating  T cell count is not signif-
icantly less than controls (p  0.12). The absolute CD3 and CD4
count increase immediately after resection, likely due to removal of
GBM-derived immunosuppressive cytokines. Surprisingly however,
individual patients show a decrease in  T cell counts at this time.
Expansion of  T cells from pre-resection GBM patients did not
differ from controls (p  0.32, n4). although  T cell expansion
was signiﬁcantly impaired after cytoreductive therapy (p  .007,
n5). Expanded  T cells retain cytotoxicity against U251 and 1047
GBM cell lines and GBM primary cultures but spare normal astro-
cytes. Expanded  T cells slow the growth of U251 intracranial
xenografts in athymic nude mice (p .008) vs sham-treated controls.
Preliminary observations suggest that growth of established U251
xenografts is slowed in selected animals as well.
Conclusions: GBM and therapy-induced immunosuppression
present a formidable barrier to systemic cellular therapy. However,
intracranial immunotherapy using expanded allogeneic  T cells
represents a potentially effective immunotherapeutic strategy against
GBM.
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SEMI-HIGH-DOSE AUTOLOGOUS AND A NON-MYELOABLATIVE RE-
DUCED INTENSITY CONDITIONING ALLOGENEIC TRANSPLANTS INTE-
GRATED IN STANDARD OR DOSE DENSE THERAPY FOR BREAST CAN-
CER: COST-EFFICIENCY ANALYSES SUPPORT DESIGN OF COST-
EFFICIENT THERAPIES
Van Hoef, M.E.H.M.1 1Transplant Creations, Amsterdam, NH, Neth-
erlands.
Introduction: DFS at 5 yr in LN BrCa depends on status at
diagnosis and is on average 60% and in MBrCa 15%. HD-auto-Tx
add signiﬁcant DFS advantage of 5% to 10% but statistically this is
not a signiﬁcant improvement of survival. In large series TRM of
HD-auto-Tx is on average 3% in the adjuvant and up to 10% in the
metastatic setting. Semi-HD is rarely associated with TRM. Alloge-
neic transplants (allo-Tx) induce an immune response in BrCa that
may eradicate minimal residual disease if the Tx is administered in
molecular remission. Based on these facts and existent collaborative
patterns we designed in 2000 a treatment plan consisting of dose
dense induction, two semi-HD-auto-Tx and a NMRICTx and de-
cided to perform upfront cost computation.
Methods: In the Netherlands a cost system is used consisting of so
named “diagnose behandelingscombinaties” (DBC) or diagnosis
treatment combinations. In general costs are to be collected for each
item or service independently. We used the therapeutic model de-
scribed here above to compute the costs of treatment and used as-
sumption based on literature data to deﬁne disease outcome at 5 yr for
premenopausal women with ER, her-2-neu negative BrCa. For
each therapy median DFS was used to deﬁne outcomes. Disease
outcomes were deﬁned as alive without disease, alive with disease,
death and toxic death. Utilities for treatment and outcome were
derived from literature; The approach followed our Markov model
design of 2001.
Results: Disease outcomes at 5 yr of LN  BrCa by respectively 4
cycles induction ChT (1), two semi-HD- auto-Tx (2) and a non-
myeloablative reduced intensity conditioning Tx (3) with donor were
anticipated to be 60%, 70% and 90% without and 15% with relapse.
DBCwere identiﬁed and included costs for ﬁrst, second and third line
ChT on outpatient basis, or with a hospital episode, costs of hormonal
therapy, of a visit without procedure, of auto- and allo- stem cell
mobilization and leukapheresis, of auto-and allo-Tx, of post Tx care,
of follow-up, of terminal care. We adjusted for the fact that the DBC
costs are based on HD- and ablative ChT whereas our approach uses
semi-HD andNMRIC respectively. The computations of the cost per
treatment with follow-up of ﬁve years showed that standard/dose
dense ChT followed by hormonal therapy adds up to  100,000 and




THE ROLE OF HUMAN CYP2B6 POLYMORPHISM IN THE BIOACTIVA-
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